05Apr/13

Emergent BioSolutions to Expand Front Line CLL Clinical Trial of TRU-016 and … – MarketWatch (press release)

Emergent BioSolutions to Expand Front Line CLL Clinical Trial of TRU-016 and
MarketWatch (press release)
“Emergent is pleased with the progress of our Phase 1b study of TRU-016 in combination with rituximab in front line patients with CLL. The strong enrollment and the encouraging early data from this open label study are expected to facilitate an

and more »

05Apr/13

Brisk walking as good as running for heart – Times of India


Times of India

Brisk walking as good as running for heart
Times of India
They found that the same energy used for moderate intensity walking and vigorous intensity running resulted in similar reductions in risk for high blood pressure, high cholesterol, diabetes, and possibly coronary heart disease over the study’s six years.
Brisk walking as good as running for heart: StudyDaily News & Analysis

all 42 news articles »

05Apr/13

Daclizumab HYP halbiert die Wahrscheinlichkeit von MS-Schüben – MyHandicap


Hannover Zeitung

Daclizumab HYP halbiert die Wahrscheinlichkeit von MS-Schüben
MyHandicap
Auf der Suche nach neuen Medikamenten gegen die schubförmige Multiple Sklerose (MS) haben Forscher unter Studienleitung der Neurologie des RUB-Klinikums St. Josef Hospital (Prof. Dr. Ralf Gold) einen erfolgversprechenden Kandidaten getestet:
Multicenterstudie: Neues Medikament könnte bei Multiple Sklerose die DMSG Multiple Sklerose Nachrichten
Erfolg versprechend: Neues Medikament gegen Multiple Sklerose – idwInformationsdienst Wissenschaft (Pressemitteilung)
Multiple Sklerose: Bochumer Wissenschaftler erforschen neue Westfalen heute

all 6 news articles »